Holen Sie sich die Stockscreener-App
133.73
0.81%
1.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$132.65
Offen:
$131.82
24-Stunden-Volumen:
5.70M
Relative Volume:
0.92
Marktkapitalisierung:
$232.75B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$13.94B
KGV:
16.76
EPS:
7.98
Netto-Cashflow:
$6.78B
1W Leistung:
+0.59%
1M Leistung:
+2.07%
6M Leistung:
+2.65%
1J Leistung:
+14.47%
1-Tages-Spanne:
$131.40
$134.96
1-Wochen-Bereich:
$127.44
$134.96
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
133.73 | 225.15B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.71 | 155.92B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
383.34 | 146.41B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
94.03 | 118.42B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
77.57 | 45.96B | 5.69B | 1.41B | 577.90M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
3 No-Brainer Dividend Stocks to Buy in September - MSN
Strs Ohio Takes $75.15 Million Position in Abbott Laboratories $ABT - MarketBeat
Carderock Capital Management Inc. Has $385,000 Stock Holdings in Abbott Laboratories $ABT - MarketBeat
McAdam LLC Lowers Stock Position in Abbott Laboratories $ABT - MarketBeat
MBL Wealth LLC Invests $314,000 in Abbott Laboratories $ABT - MarketBeat
Bella Vista teen who received heart transplant to appear in Hallmark Christmas movie - Northwest Arkansas Democrat-Gazette
Integrated Wealth Concepts LLC Has $4.64 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Sepio Capital LP Has $31.92 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
1 Green Flag for AbbVie (ABBV) Stock Right Now - The Motley Fool
SageView Advisory Group LLC Acquires 2,873 Shares of Abbott Laboratories $ABT - MarketBeat
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Encephalopathy Market Worth $209 Million in 2025 Led by - GlobeNewswire
Zurich Insurance Group Ltd FI Has $147.97 Million Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Voleon Capital Management LP - MarketBeat
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Curi RMB Capital LLC Sells 19,467 Shares of Abbott Laboratories $ABT - MarketBeat
RNC Capital Management LLC Lowers Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott medtech wins two R&D 100 awards - Medical Design & Outsourcing
Abbott reports first commercial Tendyne mitral valve implant in the U.S. - MassDevice
Abbott Laboratories $ABT Stake Raised by Great Lakes Advisors LLC - MarketBeat
Canada Post Corp Registered Pension Plan Invests $18.06 Million in Abbott Laboratories $ABT - MarketBeat
Meiji Yasuda Life Insurance Co Has $3.32 Million Holdings in Abbott Laboratories $ABT - MarketBeat
4,340 Shares in Abbott Laboratories $ABT Bought by CTC Alternative Strategies Ltd. - MarketBeat
Ashton Thomas Private Wealth LLC Purchases 2,081 Shares of Abbott Laboratories $ABT - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by NFJ Investment Group LLC - MarketBeat
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Ancora Advisors LLC Buys 1,980 Shares of Abbott Laboratories $ABT - MarketBeat
Buy Abbott Laboratories (ABT) If You’re Worried About COVID, Says Jim Cramer - MSN
Is Abbott Laboratories’s growth already priced inJuly 2025 Technicals & Expert-Curated Trade Recommendations - Lancaster City Council
Abbott-backed medical firm Domesco to pay 25% cash dividend - Theinvestor
The Zacks Analyst Blog Highlights Broadcom, T-Mobile, Abbott Laboratories, CBL & Associates Properties and Crown Crafts - Nasdaq
Investing in Abbott Laboratories (NYSE:ABT) five years ago would have delivered you a 37% gain - Yahoo Finance
Test Strip Market Overall Study Report 2025-2032 |Abbott - openPR.com
Abbott Laboratories $ABT Shares Sold by Sessa Capital IM L.P. - MarketBeat
Abbott Laboratories $ABT Stock Position Lowered by Alyeska Investment Group L.P. - MarketBeat
Top Research Reports for Broadcom, T-Mobile & Abbott - Yahoo Finance
Federation des caisses Desjardins du Quebec Sells 28,294 Shares of Abbott Laboratories $ABT - MarketBeat
Jared Moskowitz trades in Abbott Laboratories, AbbVie, and Goldman Sachs stocks - MSN
Abbott Laboratories $ABT Stock Position Reduced by DRW Securities LLC - MarketBeat
Abbott Laboratories falls after setting Q3 outlook below consensus - MSN
How to escape a deep drawdown in Abbott LaboratoriesTrade Exit Summary & Verified Short-Term Plans - Newser
Real time social sentiment graph for Abbott LaboratoriesWeekly Risk Summary & High Yield Equity Trading Tips - Newser
FDA recalls Abbott’s Heartmate power supply - BioWorld MedTech
Piper Sandler reiterates Overweight rating on Abbott Labs stock By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Overweight rating on Abbott Labs stock - Investing.com
What institutional flow reveals about Abbott LaboratoriesTrade Risk Report & Smart Money Movement Alerts - Newser
What is the target price for Abbott Laboratories stockWeekly Trade Summary & Free Community Supported Trade Ideas - خودرو بانک
Ranking Abbott Laboratories among high performing stocks via toolsGap Down & Low Risk Growth Stock Ideas - Newser
How to use a screener to detect Abbott Laboratories breakoutsPortfolio Gains Summary & Safe Entry Zone Identification - Newser
Can Abbott Laboratories deliver consistent dividends2025 Buyback Activity & Safe Capital Investment Plans - خودرو بانک
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):